Nutritive value of alfalfa (Medicago sativa L.) is limited by indigestible cell wall constituents, especially lignin. Commercially released genetically engineered alfalfa cultivars with reduced lignin (RL) concentration were developed recently by downregulation of the caffeoyl CoA 3‐O‐methyltransferase (CCoAOMT) enzyme in the lignin pathway. This research compared forage nutritive value and dry matter yield of a RL cultivar (‘HarvXtra‐008’) with non‐RL cultivars (‘54R02’ and ‘WL355RR’) across six states in the northern United States. A randomized complete block design with a split‐plot restriction on treatment randomization was used, where harvest intervals (28, 33, and 38 d) were assigned to whole plots and cultivars were the subplots. Harvest interval and cultivar effects were significant (P < 0.001) for all variables, and cultivars responded similarly across harvest intervals in that forage yield increased and nutritive value declined with increasing harvest interval. HarvXtra‐008 was consistently greater in forage nutritive value than non‐RL cultivars averaged across harvest intervals: it was 8.4% lower in acid detergent lignin, 3.5 to 7.5% lower in amylase‐treated neutral detergent fiber, and 5.3 to 7.7% greater in neutral detergent fiber digestibility, but 4.8 to 7.0% lower in dry matter yield. HarvXtra‐008 was slightly higher or similar in nutritive value and had similar or greater dry matter yield compared with non‐RL cultivars harvested on a harvest schedule 5 to 10 d earlier and more frequent. Thus, RL alfalfa can extend the time interval when it is possible to harvest forage with adequate fiber digestibility for animals with high energy requirements.

Genetically engineered alfalfa (Medicago sativa L.) cultivars with reduced lignin (RL) concentration are commercially available but their change in nutritive value as the crop matures within a growth cycle has not been thoroughly documented and might differ from non-RL cultivars. This research documents changes in forage nutritive value of a RL cultivar (HarvXtra-008) and two non-RL cultivars (54R02 and WL355RR) within five growth cycles across 2 yr in six states in the United States. A randomized complete block design with a split-plot arrangement of treatment randomization was used, with harvest growth cycles assigned to whole plots and cultivars to subplots in field trials. Cultivars were sampled on 3-to 4-d intervals between day 20 and 37 of regrowth. HarvXtra-008 was consistently lower (P ≤ .05) in acid detergent lignin (ADL) by 7-10% and amylase-treated neutral detergent fiber (aNDF) by 2-10% and 4-9% greater (P ≤ .05) in neutral detergent fiber digestibility (NDFD) than non-RL cultivars across all sampling dates. Cultivar × regrowth duration interactions (P ≤ .05) were found only for ADL and aNDF in two of the five growth cycles sampled, when regression coefficients were always smaller for HarvXtra-008 than 54R02. We calculated that the interval between harvests can be extended on average from 8 to 11 d for HarvXtra-008 compared with non-RL cultivars while maintaining adequate fiber digestibility for animals with high nutritional requirements; however, Abbreviations: ADL, acid detergent lignin; aNDF, amylase-treated neutral detergent fiber; CP, crude protein; MSC, mean stage count; NDFD, in vitro amylase-treated neutral detergent fiber digestibility; RL, reduced lignin; uNDF48, in vitro undigested amylase-treated neutral detergent fiber at 48 h. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Objectives: The current demographic information from China reports that 10%-19% of patients hospitalized with coronavirus disease (COVID-19) were diabetic. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are considered firstline agents in patients with diabetes because of their nephroprotective effects, but administration of these drugs leads to upregulation of angiotensin-converting enzyme 2 (ACE2), which is responsible for the viral entry of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2). Data are lacking to determine what pulmonary effects ACEIs or ARBs may have in patients with diabetes, which could be relevant in the management of patients infected with SARS-CoV-2. This study aims to assess the prevalence of pulmonary adverse drug effects (ADEs) in patients with diabetes who were taking ACEI or ARBs to provide guidance as to how these medications could affect outcomes in acute respiratory illnesses such as SARS-CoV-2 infection. Methods: 1DATA, a unique data platform resulting from collaboration across veterinary and human health care, used an intelligent medicine recommender system (1DrugAssist) developed using several national and international databases to evaluate all ADEs reported to the Food and Drug Administration for patients with diabetes taking ACEIs or ARBs. Results: Mining of this data elucidated the proportion of a cluster of pulmonary ADEs associated with specific medications in these classes, which may aid health care professionals in understanding how these medications could worsen or predispose patients with diabetes to infections affecting the respiratory system, specifically COVID-19. Based on this data mining process, captopril was found to have a statistically significantly higher incidence of pulmonary ADEs compared with other ACEIs (P ¼ 0.005) as well as ARBs (P ¼ 0.012), though other specific drugs also had important pulmonary ADEs associated with their use. Conclusion: These analyses suggest that pharmacists and clinicians will need to consider the specific medication's adverse event profile, particularly captopril, on how it may affect infections and other acute disease states that alter pulmonary function, such as COVID-19.

No abstract

This study presents a new way to investigate comprehensive trends in cancer nanotechnology research in different countries, institutions, and journals providing critical insights to prevention, diagnosis, and therapy. This paper applied the qualitative method of bibliometric analysis on cancer nanotechnology using the PubMed database during the years 2000–2021. Inspired by hybrid medical models and content-based and bibliometric features for machine learning models, our results show cancer nanotechnology studies have expanded exponentially since 2010. The highest production of articles in cancer nanotechnology is mainly from US institutions, with several countries, notably the USA, China, the UK, India, and Iran as concentrated focal points as centers of cancer nanotechnology research, especially in the last five years. The analysis shows the greatest overlap between nanotechnology and DNA, RNA, iron oxide or mesoporous silica, breast cancer, and cancer diagnosis and cancer treatment. Moreover, more than 50% of the information related to the keywords, authors, institutions, journals, and countries are considerably investigated in the form of publications from the top 100 journals. This study has the potential to provide past and current lines of research that can unmask comprehensive trends in cancer nanotechnology, key research topics, or the most productive countries and authors in the field.